Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Open Access
- 1 May 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 8 (4), 1-9
- https://doi.org/10.1038/s41408-018-0071-x
Abstract
In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced deeper responses vs. lenalidomide and dexamethasone alone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM). We report a subgroup analysis of East Asian (Japanese, Korean, and Taiwanese) patients from POLLUX based on a longer follow-up of 24.7 months. Median progression-free survival was not reached (NR) for DRd vs. 13.8 months for Rd (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.23-0.76), and overall response rates were higher for DRd vs. Rd (90.2 vs. 72.1%). DRd extended the median duration of response vs. Rd (NR vs. 20.2 months), and minimal residual disease-negative rates at the 10-5 sensitivity threshold were 21.2 vs. 9.1% for DRd vs. Rd. No new safety signals were observed. Similar efficacy and safety were observed in the smaller subgroup of Japanese patients treated with DRd vs. Rd. These results demonstrate favorable efficacy and safety of DRd vs. Rd in East Asian patients and also in the Japanese-only patient subgroup that are consistent with findings in the overall patient population of POLLUX.This publication has 19 references indexed in Scilit:
- Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaBlood, 2017
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-LinkingPublished by The American Association of Immunologists ,2016
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaBlood, 2016
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyondImmunological Reviews, 2016
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialThe Lancet, 2016
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaNew England Journal of Medicine, 2015
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomamAbs, 2015
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsPublished by The American Association of Immunologists ,2011